NMG
ITCI

New Millennium Group’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

New Millennium Group’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-15,587
Closed -$987K – 426
2023
Q2 		$987K Buy
+15,587
New +$971K 0.91% 26

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

New Millennium Group's ITCI Position: Q3 2023 in Review

New Millennium Group sold out of Intra-Cellular Therapies Inc. (ITCI) in Q3 2023, closing a stake of 15,587 shares — an estimated $987K sold.

New Millennium Group first reported a position in ITCI in Q2 2023 and held it in 1 quarter. The position peaked at $987K in Q2 2023. 292 funds tracked by Wall St. Rank hold ITCI as of Q3 2023.

  • New Millennium Group reported no remaining Intra-Cellular Therapies Inc. position as of Q3 2023 after selling out during the quarter.
  • New Millennium Group sold 15,587 Intra-Cellular Therapies Inc. shares in Q3 2023, an estimated $987K.
  • New Millennium Group first reported a position in Intra-Cellular Therapies Inc. in Q2 2023 and held it in 1 quarter.
  • New Millennium Group's Intra-Cellular Therapies Inc. position peaked at $987K in Q2 2023.
  • 292 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q3 2023.

Based on New Millennium Group's 13F filing for Q3 2023, filed 13 Nov 2023.